Category : Search result: Pfizer R

Pfizer Spent Just 18% on R&D in 2024, While 27% Went to Shareholders

Pfizer spent 18% on R&D, 27% to shareholders in 2024

Analysis reveals US pharma giant Pfizer allocated more revenue to shareholders than R&D in 2024, as Trump's drug price rhetoric targets allies over corporate profits. Explore the real drivers of high US medicine costs.

Novo Nordisk Challenges Pfizer in High-Stakes Bid for Obesity Biotech Metsera

Novo Nordisk Bids for Metsera, Challenging Pfizer's Offer

Danish pharmaceutical giant Novo Nordisk has entered a bidding war with Pfizer for obesity-focused biotech firm Metsera, potentially disrupting the US company's planned acquisition in a major power play for obesity treatment dominance.

Page 1 of 1